A Single-centre. Double-blind, Placebo Controlled Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Repeat Doses of Nebulised GSK2269557 in Healthy Male Subjects.
Latest Information Update: 10 Dec 2023
At a glance
- Drugs Nemiralisib (Primary) ; Nemiralisib (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 25 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2012 Actual patient number changed from 59 to 61 according to ClinicalTrials.gov.